Literature DB >> 33861436

Intravenous Curcumin Mitigates Atherosclerosis Progression in Cholesterol-Fed Rabbits.

Amir Abbas Momtazi-Borojeni1, Narges Amel Zabihi2, Ramin Khameneh Bagheri3, Muhammed Majeed4, Tannaz Jamialahmadi5,6, Amirhossein Sahebkar7,8,9,10.   

Abstract

Orally administered curcumin has been found to have a moderate therapeutic effect on dyslipidemia and atherosclerosis. The present study was conducted to determine lipid-modulating and antiatherosclerosis effects of injectable curcumin in the rabbit model of atherosclerosis induced by a high cholesterol diet (HCD). New Zealand white male rabbits were fed on a normal chow enriched with 0.5% (w/w) cholesterol for 8 weeks. Atherosclerotic rabbits were randomly divided into three groups, including a control group receiving intravenous (IV) injection of the saline buffer, two treatment groups receiving IV administration of the injectable curcumin at low (1 mg/kg/week) and high (10 mg/kg/week) over 4 weeks. Plasma lipid parameters, including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and total cholesterol (TC) were measured. Aortic arch atherosclerotic lesions were assessed using hematoxylin and eosin (H&E) staining. The low dose of curcumin significantly reduced plasma levels of TC, LDL-C, and TG by -14.19 ± 5.19%, -6.22 ± 1.77%, and - 29.84 ± 10.14%, respectively, and increased HDL-C by 14.05 ± 6.39% (p < 0.05). High dose of curcumin exerted greater lipid-modifying effects, in which plasma levels of TC, LDL-C, and TG were significantly (p < 0.05) decreased by -56.59 ± 10.22%, -44.36 ± 3.24%, and - 25.92 ± 5.57%, respectively, and HDL-C was significantly increased by 36.24 ± 12.5%. H&E staining showed that the lesion severity was lowered significantly in the high dose (p = 0.03) but not significantly (p > 0.05) in the low-dose curcumin groups, compared to control rabbits. The median (interquartile range) of plaque grades in the high dose and low dose, and control groups was found to be 2 [2-3], 3 [2-3], and 4 [3-4], respectively. The injectable curcumin could significantly improve dyslipidemia and alleviate atherosclerotic lesion in HCD-induced atherosclerotic rabbits.

Entities:  

Keywords:  Atherosclerosis; Curcumin; High cholesterol diet; Rabbit dyslipidemia

Mesh:

Substances:

Year:  2021        PMID: 33861436     DOI: 10.1007/978-3-030-64872-5_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  55 in total

Review 1.  Statins and hepatotoxicity: focus on patients with fatty liver.

Authors:  Naga Chalasani
Journal:  Hepatology       Date:  2005-04       Impact factor: 17.425

Review 2.  Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.

Authors:  Sundararajan Srikanth; Prakash Deedwania
Journal:  Curr Hypertens Rep       Date:  2016-10       Impact factor: 5.369

Review 3.  Statins as a possible cause of inflammatory and necrotizing myopathies.

Authors:  Santosh Padala; Paul D Thompson
Journal:  Atherosclerosis       Date:  2011-11-16       Impact factor: 5.162

Review 4.  Curcumin and liver cancer: a review.

Authors:  Altaf S Darvesh; Bharat B Aggarwal; Anupam Bishayee
Journal:  Curr Pharm Biotechnol       Date:  2012-01       Impact factor: 2.837

Review 5.  Immune modulation by curcumin: The role of interleukin-10.

Authors:  Hamid Mollazadeh; Arrigo F G Cicero; Christopher N Blesso; Matteo Pirro; Muhammed Majeed; Amirhossein Sahebkar
Journal:  Crit Rev Food Sci Nutr       Date:  2017-09-06       Impact factor: 11.176

Review 6.  Therapeutic effects of curcumin in inflammatory and immune-mediated diseases: A nature-made jack-of-all-trades?

Authors:  Elham Abdollahi; Amir Abbas Momtazi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  J Cell Physiol       Date:  2017-03-31       Impact factor: 6.384

Review 7.  HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins.

Authors:  Allan Gaw
Journal:  Cardiovasc Drugs Ther       Date:  2003-01       Impact factor: 3.727

Review 8.  Atherogenic dyslipidemia: cardiovascular risk and dietary intervention.

Authors:  Kiran Musunuru
Journal:  Lipids       Date:  2010-06-04       Impact factor: 1.880

Review 9.  Curcumin as "Curecumin": from kitchen to clinic.

Authors:  Ajay Goel; Ajaikumar B Kunnumakkara; Bharat B Aggarwal
Journal:  Biochem Pharmacol       Date:  2007-08-19       Impact factor: 5.858

Review 10.  Curcumin: updated molecular mechanisms and intervention targets in human lung cancer.

Authors:  Ming-Xiang Ye; Yan Li; Hong Yin; Jian Zhang
Journal:  Int J Mol Sci       Date:  2012-03-22       Impact factor: 6.208

View more
  1 in total

Review 1.  NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics.

Authors:  Na Lu; Weijia Cheng; Dongling Liu; Gang Liu; Can Cui; Chaoli Feng; Xianwei Wang
Journal:  Front Cell Dev Biol       Date:  2022-04-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.